Evidence map›Paper›PMID 33757899›Full record

ArticleBone2021

Bisphosphonates in dentistry: Historical perspectives, adverse effects, and novel applications.

Parish P Sedghizadeh, Shuting Sun, Allan C Jones, Esmat Sodagar, Philip Cherian, Casey Chen, Adam F Junka, Jeffrey D Neighbors, Charles E McKenna, R Graham G Russell and 1 more

Open access · greenAbstract read
In one paragraph

Article in Bone, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Bisphosphonates for delivering drugs to bone.British journal of pharmacology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Parish P SedghizadehDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, United States of America. Electronic address: sedghiza@usc.edu.
Shuting SunBioVinc LLC, Pasadena, California, United States of America.
Allan C JonesGeneral Dental Practice; Torrance, California, United States.
Esmat SodagarDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, United States of America.
Philip CherianBioVinc LLC, Pasadena, California, United States of America.
Casey ChenDivision of Periodontology, Diagnostic Sciences & Dental Hygiene, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, United States of America.
Adam F JunkaDepartment of Pharmaceutical Microbiology and Parasitology, Medical University of Wroclaw; Wroclaw Research Centre EIT, Wroclaw, Poland.
Jeffrey D NeighborsBioVinc LLC, Pasadena, California, United States of America; Department of Pharmacology and Medicine, Pennsylvania State University College of Medicine, Hershey, PA, United States of America.
Charles E McKennaDepartment of Chemistry, University of Southern California, Los Angeles, CA, United States of America.
R Graham G RussellThe Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, United Kingdom; The Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, University of Sheffield, United Kingdom.
Frank H EbetinoBioVinc LLC, Pasadena, California, United States of America. Electronic address: halebetino@biovinc.com.
BioVinc (United States) · USUniversity of Southern California · USRetina Macula Institute · USUniversity of Oxford · GBWroclaw Medical University · PL

Funding

Bone targeted delivery of an antimicrobial drug for osteomyelitis therapyR44AI125060 · NIAID · BIOVINC, LLC · PI EBETINO, FRANK H. · 2020 to 2022
$3.0M
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatmentR42DE025789 · NIDCR · BIOVINC, LLC · PI EBETINO, FRANK H., SEDGHIZADEH, PARISH PAYMON · 2017 to 2018
$1.5M
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatmentR41DE025789 · NIDCR · BIOVINC, LLC · PI EBETINO, FRANK H., SEDGHIZADEH, PARISH PAYMON · 2016 to 2016
$150k
NIAID NIH HHS R44 AI125060NIDCR NIH HHS R41 DE025789NIDCR NIH HHS R42 DE025789
6 · The paper itself

Abstract

Studies of the potential role of bisphosphonates in dentistry date back to physical chemical research in the 1960s, and the genesis of the discovery of bisphosphonate pharmacology in part can be linked to some of this work. Since that time, parallel research on the effects of bisphosphonates on bone metabolism continued, while efforts in the dental field included studies of bisphosphonate effects on dental calculus, caries, and alveolar bone loss. While some utility of this drug class in the dental field was identified, leading to their experimental use in various dentrifice formulations and in some dental applications clinically, adverse effects of bisphosphonates in the jaws have also received attention. Most recently, certain bisphosphonates, particularly those with strong bone targeting properties, but limited biochemical effects (low potency bisphosphonates), are being studied as a local remedy for the concerns of adverse effects associated with other more potent members of this drug class. Additionally, low potency bisphosphonate analogs are under study as vectors to target active drugs to the mineral surfaces of the jawbones. These latter efforts have been devised for the prevention and treatment of oral problems, such as infections associated with oral surgery and implants. Advances in the utility and mechanistic understanding of the bisphosphonate class may enable additional oral therapeutic options for the management of multiple aspects of dental health.

Indexed as

Bone Density Conservation AgentsDrug-Related Side Effects and Adverse ReactionsBone and BonesDentistryDiphosphonatesHumansBone Density Conservation AgentsDiphosphonatesBisphosphonateBone targeting conjugatesDentistryPyrophosphate

Identifiers

PMID33757899
PMCPMC8076070
OpenAlexW3137389269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.